Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study

BACKGROUND/AIMS: The efficacy and safety of vedolizumab in moderate to severely active ulcerative colitis (UC) have been demonstrated in the GEMINI 1 study (NCT00783718). This post-hoc exploratory analysis sought to establish the efficacy and safety of vedolizumab in a subgroup of patients from Asia...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Intest Res
Hlavní autoři: Ooi, Choon Jin, Hilmi, Ida Normiha, Kim, Hyo-Jong, Jalihal, Umesh, Wu, Deng-Chyang, Demuth, Dirk, Lindner, Dirk, Adsul, Shashi
Médium: Artigo
Jazyk:Inglês
Vydáno: Korean Association for the Study of Intestinal Diseases 2021
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7873399/
https://ncbi.nlm.nih.gov/pubmed/32877600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2019.09159
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky